Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma
International Journal of Molecular Sciences · 13.08.2025 · 26 (16) · 7836
DOI: 10.3390/ijms26167836 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.08.2025. Verfasst von Yusra Zarlashat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Tumor Microenvironment, Liver Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union - Next Generation EU, Mission 4, Component 1, European Union—Next Generation EU, Mission 4, Component 1.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most common liver cancer, with poor survival rates in advanced stages due to late diagnosis, tumor heterogeneity, and therapy resistance. The tumor microenvironment (TME) in HCC has a crucial role in tumor progression, characterized by a complex interaction of immune cells, stromal components, and immunosuppressive signaling pathways. Chronic inflammation driven by viral infections, metabolic dysfunction, and alcohol consumption triggers an immunosuppressive TME, promoting immune evasion and tumor growth. Immune cell populations, such as myeloid-derived suppressor cells, regulatory T cells, and tumor-associated macrophages, contribute to immunosuppression, while cytotoxic T lymphocytes and natural killer cells exert anti-tumor effects. Recent advances in immunotherapy, mainly immune checkpoint inhibitors (ICIs) targeting programmed death-ligand 1 and programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4, have revolutionized HCC treatment, though response rates remain limited. Combined therapies using tyrosine kinase inhibitors, anti-angiogenic agents, and ICIs improve patient outcomes. This review discusses the immunological mechanisms contributing to HCC progression, the role of immune cell subsets in tumor evasion, and therapeutic interventions, from conventional treatments to advanced immunotherapies. Ongoing clinical trials, barriers to effective treatment, and future directions to enhance HCC management and patient survival will also be overviewed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan.
- Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, 73100 Lecce, Italy.
- Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
- Department of Medicine and Surgery, LUM University, 70010 Casamassima, Italy.
ORCID-Profile: Yusra Zarlashat, Flora Guerra, Anna Picca
Förderung
- European Union - Next Generation EU, Mission 4, Component 1
- European Union—Next Generation EU, Mission 4, Component 1
Zitieren
APA
Zarlashat, Y., Ghaffar, A., Guerra, F., & Picca, A. (2025). Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 26(16), 7836. https://doi.org/10.3390/ijms26167836
Vancouver
Zarlashat Y, Ghaffar A, Guerra F, Picca A. Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2025;26(16):7836. doi:10.3390/ijms26167836
BibTeX
@article{Zarlashat2025,
author = {Zarlashat, Yusra and Ghaffar, Abdul and Guerra, Flora and Picca, Anna},
title = {Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {16},
pages = {7836},
doi = {10.3390/ijms26167836}
}
EUVIMED